Clinical Trial Update: Dose-finding Study of ASP2151 in Subjects With Herpes Zoster [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of ASP2151 in subjects with herpes zoster has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• ASP2151

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Herpes Zoster | Phase 2 | Status: COMPLETED